Agilent Acquires Seahorse for $235 Million

Santa Clara, Calif.-based Agilent Technologies has agreed to acquire Seahorse Bioscience, a provider of instruments and assay kits for measuring cell metabolism and bioenergetics, for $235 million.

Seahorse’s metabolic analyzers, equipped with XF technology, will complement Agilent’s separations and mass spectrometry solutions.

The XF technology helps researchers understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug by providing real-time kinetics to unlock essential cellular bioenergetics data.

“The combination of these two platforms gives scientists a more comprehensive and faster path to researching the most challenging diseases,” says Patrick Kaltenbach, president of Agilent’s Life Sciences and Applied Markets Group. — Michael Cipriano